Mahdis Habibpour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahdis Habibpour has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bjoern Michael Eskofier
Friedrich-Alexander-Universität Erlangen-Nürnberg
2 shared publications - Alexandros Tanzanakis
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
1 shared publication - Amirreza Asemanrafat
Department Machine Learning and Data Analytics Lab, Artificial Intelligence in Biomedical Engineering, Friedrich Alexander University Erlangen-Nuremberg, 91052 Erlangen, Germany
1 shared publication - Arnd Kleyer
Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
1 shared publication - Emmanuelle Salin
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
1 shared publication - Fatemeh Salehi
Department Machine Learning and Data Analytics Lab, Artificial Intelligence in Biomedical Engineering, Friedrich Alexander University Erlangen-Nuremberg, 91052 Erlangen, Germany
1 shared publication
Latest Publications
- 2 August 2026
- Published by Springer Nature
- p. 272-276
Predicting Numeric Hemoglobin A1c for Individualized Type 2 Diabetes Care Using Machine Learning: A MIMIC-IV Study
- 2 August 2026
- Published by Springer Nature
- p. 272-276
Predicting Numeric Hemoglobin A1c for Individualized Type 2 Diabetes Care Using Machine Learning: A MIMIC-IV Study
- Open Access
- 8 August 2025
- Published by MDPI AG in Technologies
- Vol. 13 (8) , 350
Predicting Disease Activity Score in Rheumatoid Arthritis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs Using Machine Learning Models
Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by joint inflammation and progressive disability. While biological disease-modifying antirheumatic drugs (bDMARDs) have significantly improved disease control, predicting individual treatment response remains clinically challenging. This study presents a machine learning approach to predict 12-month disease activity, measured by DAS28-CRP, in RA patients beginning bDMARD therapy. We trained and evaluated eight regression models, including Ridge, Lasso, Support Vector Regression, and XGBoost, using baseline clinical features from 154 RA patients treated at University Hospital Erlangen. A rigorous nested cross-validation strategy was applied for internal model selection and validation. Importantly, model generalizability was assessed using an independent external dataset from the Austrian BioReg registry, which includes a more diverse, real-world RA patient population from across multiple clinical sites. The Ridge regression model achieved the best internal performance (MAE: 0.633, R2: 0.542) and showed strong external validity when applied to unseen BioReg data (MAE: 0.678, R2: 0.491). These results indicate robust cross-cohort generalization. By predicting continuous DAS28-CRP scores instead of binary remission labels, our approach supports flexible, individualized treatment planning based on local or evolving clinical thresholds. This work demonstrates the feasibility and clinical value of externally validated, data-driven tools for precision treatment planning in RA.
- 8 August 2025
- Published by MDPI AG in Technologies
- Vol. 13 (8) , 350
Open AccessPredicting Disease Activity Score in Rheumatoid Arthritis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs Using Machine Learning Models
Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by joint inflammation and progressive disability. While biological disease-modifying antirheumatic drugs (bDMARDs) have significantly improved disease control, predicting individual treatment response remains clinically challenging. This study presents a machine learning approach to predict 12-month disease activity, measured by DAS28-CRP, in RA patients beginning bDMARD therapy. We trained and evaluated eight regression models, including Ridge, Lasso, Support Vector Regression, and XGBoost, using baseline clinical features from 154 RA patients treated at University Hospital Erlangen. A rigorous nested cross-validation strategy was applied for internal model selection and validation. Importantly, model generalizability was assessed using an independent external dataset from the Austrian BioReg registry, which includes a more diverse, real-world RA patient population from across multiple clinical sites. The Ridge regression model achieved the best internal performance (MAE: 0.633, R2: 0.542) and showed strong external validity when applied to unseen BioReg data (MAE: 0.678, R2: 0.491). These results indicate robust cross-cohort generalization. By predicting continuous DAS28-CRP scores instead of binary remission labels, our approach supports flexible, individualized treatment planning based on local or evolving clinical thresholds. This work demonstrates the feasibility and clinical value of externally validated, data-driven tools for precision treatment planning in RA.